Buscar resultados de ensayos clínicos
Immunoblastic Lymphadenopathy - 269 Studies Found
Estado | Estudiar |
Completed |
Nombre del estudio: Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Condición:
|
Terminated |
Nombre del estudio: 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma Condición:
|
Completed |
Nombre del estudio: Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma Condición:
|
Recruiting |
Nombre del estudio: A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) Condición:
Intervenciones: Drug: Brentuximab vedotin study drug given intravenously to determine efficacy in study diseases |
Completed |
Nombre del estudio: 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma Condición:
|
Completed |
Nombre del estudio: A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma Condición: Untreated T-cell Angioimmunoblastic Lymphoma Fecha: 2005-09-12 Intervenciones:
|
Completed |
Nombre del estudio: Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma Condición: Lymphoma Fecha: 2009-08-12 Intervenciones:
|
Terminated |
Nombre del estudio: Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma Condición: Lymphoma Fecha: 2003-10-03 Intervenciones: Drug: cyclosporine Cyclosporine doses will be based on actual body weight unless actual body weight is & |
Recruiting |
Nombre del estudio: Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma Condición:
|
Completed |
Nombre del estudio: Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Condición:
|